S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|BioCryst Pharmaceuticals Prices Public Offering of Common Stock ()|
|BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases (NIAID) to Develop BCX4430 for the Treatment of Marburg Virus Disease (2013/9/17)|
|BioCryst Provides Corporate Update and Reports Second Quarter 2013 Financial Results (2013/8/8)|
|BioCryst Announces Full Exercise of over Allotment Option (2013/8/5)|
|BioCryst to Present at Morgan Stanley Global Healthcare Conference (2013/9/3)|
|BioCryst Announces Proposed Public Offering of Common Stock (2013/7/30)|
|BioCryst to Announce Second Quarter 2013 Financial Results August 8 (2013/8/1)|
|BioCryst Provides Corporate Update and Reports Third Quarter 2013 Financial Results (2013/11/5)|
|BioCryst Initiates OPuS-1: a Phase 2a Clinical Trial of BCX4161 in Patients with Hereditary Angioedema (2013/11/7)|
|BioCryst to Present at Two Upcoming Investor Conferences (2013/11/20)|
Click above to view more mutual fund data and stats for bcrx - Biocryst Pharmaceuticals.